Pharma sales comp lives inside a regulatory envelope that non-pharma plans don\'t face. Incentives that look normal in SaaS or industrial sales — volume bonuses, aggressive accelerators, deal-level SPIFFs — can violate anti-kickback statute or PhRMA code in pharma contexts. The FDA, OIG, and state attorneys general have driven multi-hundred-million-dollar settlements against companies whose comp plans crossed those lines, often in ways that seemed benign at design time.
This checklist walks through 12 compliance gates specific to pharma sales comp. Each gate is weighted by regulatory exposure. Score shows readiness band; output lists missing gates ranked by weight with specific fix guidance tied to the regulatory source.
The four categories and weighting
Anti-kickback & regulatory (weight 3)
Highest weight. The federal Anti-Kickback Statute (42 USC 1320a-7b) and state analogs prohibit offering or receiving anything of value to induce prescribing of federally-reimbursed drugs. Comp plans that pay per-Rx or tie bonuses to prescriber influence can create criminal exposure — fines, CIAs, individual-rep and executive liability.
PhRMA code alignment (weight 2)
Voluntary code but effectively mandatory for member companies. Covers promotional materials, sample handling, speaker programs, meal/gift limits, HCP interactions. Comp plans that incentivize non-compliant behavior (e.g., high-volume sample distribution, off-label promotion) trigger code violations.
Fair balance & promotional accuracy (weight 2)
Required by FDA regulation (21 CFR 202.1). Sales reps must present risks alongside benefits; promotional claims must be supported by approved labeling. Comp plans that reward "closing prescriptions" without quality gates create pressure for reps to shortcut fair balance.
Territory & data integrity (weight 2)
Pharma-specific operational controls: prescriber data (IQVIA / Symphony) usage agreements, sample accountability, aggregate spend reporting (Sunshine Act / Open Payments). Comp plans that rely on unauthorized data or create incentives to mishandle samples create downstream compliance exposure.
Anti-kickback weight-3 reflects real enforcement history — Pfizer ($2.3B), GSK ($3B), J&J ($2.2B), Novartis ($678M) settlements over the past two decades all involved comp-plan incentives that crossed regulatory lines. Individual reps and managers have faced personal liability under the Responsible Corporate Officer doctrine. Weight-3 gates aren\'t "nice to have"; they\'re the difference between a compliant program and a DOJ consent decree.
Pharma Plan Checklist
12 compliance gates. Check the ones genuinely in place. Score shows exposure.
ℹ️ How this checklist works +
The question it answers: Where does my pharma sales comp plan expose us to anti-kickback, PhRMA code, FDA promotional, or data-integrity risk — and what specifically do I need to fix?
What to do:
- Walk the 12 gates. Check only the ones genuinely implemented (not planned-to-be-implemented).
- Weight scale: Weight 3 = anti-kickback / regulatory (highest exposure). Weight 2 = PhRMA, fair balance, data integrity.
What you\'ll get back:
- 0–100% weighted readiness score with band: Compliant ≥90 / Mostly Ready ≥75 / Gaps ≥50 / High Risk <50.
- Missing gates ranked by weight with specific fix guidance tied to regulatory source.
This tool is directional. Validate with your Compliance and Legal counsel before finalizing any pharma comp plan — regulatory interpretation varies by drug class, patient population, and state.
How to act on your score
Compliant (≥90%)
Structural controls are in place. Remaining gaps likely operational details. Keep cadence — pharma comp requires ongoing vigilance as regulations evolve (OIG advisory opinions, state laws, FDA guidance updates).
Mostly Ready (75–89%)
A few specific gates trail. Close weight-3 gaps before the next plan cycle; weight-2 gaps can be targeted over 2–3 quarters. Any open weight-3 gate is a material risk until closed.
Gaps (50–74%)
Material compliance exposure. If weight-3 gates are open, engage external counsel now and stop any incentive components tied to those gaps until remediated. Weight-2 issues add up — multiple open weight-2 gates create pattern exposure.
High Risk (<50%)
Serious exposure. The combination of open weight-3 gates at scale is what triggers DOJ attention. Pause new incentive rollouts, engage external employment and healthcare regulatory counsel immediately, and plan for substantial program redesign — not a quick patch.
Under the Responsible Corporate Officer doctrine, individuals who "had the authority and opportunity to prevent or correct a violation" can face personal criminal liability — including SalesOps leaders and comp-plan designers. If you\'re designing a pharma comp plan, your personal exposure is real. Weight-3 gate failures aren\'t just company risk; they\'re career risk.
Designing a pharma comp plan?
We work with pharma SalesOps and Compliance teams to stress-test comp plans against regulatory requirements. Book a 20-minute review before launching.
Book a 20-minute consultation →FAQ
Partially. Anti-kickback statute applies to all federally-reimbursed products. PhRMA code is pharma-specific; AdvaMed code covers medical devices with similar-but-not-identical rules. Diagnostics have additional specific regulations. Use this as a directional framework; consult device-specific counsel for those segments.
Yes within limits. Launch incentives are allowed; what\'s not allowed is paying per-Rx, paying based on prescriber influence on specific formulary decisions, or paying for off-label promotion. Volume-based bonuses tied to legitimate promotional activity (calls made, approved messaging delivered) are generally acceptable.
Not directly to rep comp, but yes to rep interactions with HCPs (meals, educational materials, honoraria). Rep comp plans that incentivize high volumes of these activities create aggregate-spend reporting obligations — not illegal, but operationally complex and subject to public disclosure.
Targeting itself is fine. What\'s not fine is using analytics to identify high-Rx-potential prescribers and then paying reps specifically based on influence metrics against those targets — that\'s the exact shape of multiple settled cases. Keep rep comp tied to activity, not Rx outcomes in federally-reimbursed products.